References
1. Bartlett AW, Cann MP, Yeoh DK,
Bernard A, Ryan AL, Blyth CC, et al. Epidemiology of invasive fungal
infections in immunocompromised children; an Australian national,10 year
review. Pediatr Blood Cancer. 2019;66(4):e27564.
2. Wasmann RE, Muilwijk EW, Burger DM,
Verweij PE, Knibbe CA, Bruggemann RJ. Clinical Pharmacokinetics and
Pharmacodynamics of Micafungin. Clinical pharmacokinetics.
2018;57(3):267-86.
3. Groll AH. Efficacy and safety of
antifungals in pediatric patients. Early human development. 2011;87
Suppl 1:S71-4.
4. Tissot F, Agrawal S, Pagano L,
Petrikkos G, Groll AH, Skiada A, et al. ECIL-6 guidelines for the
treatment of invasive candidiasis, aspergillosis and mucormycosis in
leukemia and hematopoietic stem cell transplant patients. Haematologica.
2017;102(3):433-44.
5. Maertens JA, Girmenia C, Bruggemann
RJ, Duarte RF, Kibbler CC, Ljungman P, et al. European guidelines for
primary antifungal prophylaxis in adult haematology patients: summary of
the updated recommendations from the European Conference on Infections
in Leukaemia. The Journal of antimicrobial chemotherapy.
2018;73(12):3221-30.
6. García Morin M, Cela E, Garrido C,
et al. Trasplante de médula ósea en pacientes con anemia falciforme.
Experiencia en un centro [Bone marrow transplant in patients with
sickle cell anaemia. Experience in one centre]. An Pediatr (Barc).
2017;86(3):142-150.
7. Noè A, Cappelli B, Biffi A, et al.
High incidence of severe cyclosporine neurotoxicity in children affected
by haemoglobinopaties undergoing myeloablative haematopoietic stem cell
transplantation: early diagnosis and prompt intervention ameliorates
neurological outcome. Ital J Pediatr . 2010;36:14.
8. Gluckman E, Cappelli B, Bernaudin
F, Labopin M, Volt F, Carreras J, et al. Sickle cell disease: an
international survey of results of HLA-identical sibling hematopoietic
stem cell transplantation. Blood. 2017;129(11):1548-56.
9. Paciaroni K, De Angelis G, Gallucci
C, Alfieri C, Ribersani M, Roveda A, et al. Invasive pulmonary
aspergillosis in a haematopoietic stem cell transplant recipient with
sickle cell disease: a successful treatment. Mediterr J Hematol
Infect Dis . 2015;7(1):e2015006.
10. Goussetis E, Efstathiou E,
Paisiou A, Avgerinou G, Zisaki K, Giamouris VJ, et al. Infectious
complications following allogeneic stem cell transplantation by using
anti-thymocyte globulin-based myeloablative conditioning regimens in
children with hemoglobinopathies. Transpl Infect Dis .
2015;17(2):201-207.
11. Al Otaibi FE. Fatal case of
cerebral aspergilloma complicated by ventriculitis and bacteremia due to
Salmonella species in a sickle cell disease patient. Saudi Med J .
2018;39(9):935-939.
12. Passweg JR, Baldomero H, Basak
GW, Chabannon C, Corbacioglu S, Duarte R, et al. The EBMT activity
survey report 2017: a focus on allogeneic HCT for nonmalignant
indications and on the use of non-HCT cell therapies. Bone Marrow
Transplant . 2019;54(10):1575-1585.
13. Gonzalo Pascual H, Ponce Salas B, Rincón López EM, Santiago García
B, Garrido Colino C, Hernández-Sampelayo Matos T. Infección fúngica
invasora en pacientes hematooncológicos: revisión de 10 años.
Communication poster presented in VIII Congress of the Spanish Society
of Pediatric Infectology (SEIP) and VII Hispano-Mexican Meeting of
Pediatric Infectious Diseases. 2016 Mar 3-5; Valencia, Spain.
14. Molina JR, Serrano J,
Sanchez-Garcia J, Rodriguez-Villa A, Gomez P, Tallon D, et al.
Voriconazole as primary antifungal prophylaxis in children undergoing
allo-SCT. Bone Marrow Transplant . 2012;47(4):562-567.
15. Gwee A, Cranswick N, Curtis N.
Posaconazole: promising but problematic in practice in pediatric
patients. Pediatr Infect Dis J . 2015;34(6):604-606.
16. Heinz WJ, Cabanillas Stanchi KM,
Klinker H, et al. Posaconazole plasma concentration in pediatric
patients receiving antifungal prophylaxis after allogeneic hematopoietic
stem cell transplantation. Med Mycol . 2016;54(2):128-137.
17. Kobayashi C, Hanadate T, Niwa T,
Yoshiyasu T, So M, Matsui K. Safety and Effectiveness of Micafungin in
Japanese Pediatric Patients: Results of a Postmarketing Surveillance
Study. J Pediatr Hematol Oncol . 2015;37(5):e285-e291.
18. Viscoli C, Bassetti M, Castagnola
E, et al. Micafungin for the treatment of proven and suspected invasive
candidiasis in children and adults: findings from a multicenter
prospective observational study. BMC Infect Dis . 2014;14:725.
19. Kotsopoulou M, Papadaki C,
Anargyrou K, et al. Effectiveness and Safety of Micafungin in Managing
Invasive Fungal Infections among Patients in Greece with Hematologic
Disorders: The ASPIRE Study. Infect Dis Ther . 2019;8(2):255-268.
20. Albano E, Azie N, Roy M, Townsend
R, Arrieta A. Pharmacokinetic and safety profiles of repeated-dose
prophylactic micafungin in children and adolescents undergoing
hematopoietic stem cell transplantation. J Pediatr Hematol Oncol .
2015;37(1):e45-e50.
21. Scott LJ. Micafungin: A Review in
the Prophylaxis and Treatment of Invasive Candida Infections in
Paediatric Patients. Paediatr Drugs . 2017;19(1):81-90.
22. Bochennek K, Balan A,
Müller-Scholden L, et al. Micafungin twice weekly as antifungal
prophylaxis in paediatric patients at high risk for invasive fungal
disease. J Antimicrob Chemother . 2015;70(5):1527-1530.
23. Chandra S, Fukuda T, Mizuno K, et
al. Micafungin antifungal prophylaxis in children undergoing HSCT: can
we give higher doses, less frequently? A pharmacokinetic study. J
Antimicrob Chemother . 2018;73(6):1651-1658..
24. Hope WW, Seibel NL, Schwartz CL,
et al. Population pharmacokinetics of micafungin in pediatric patients
and implications for antifungal dosing. Antimicrob Agents
Chemother . 2007;51(10):3714-3719.
25. Mehta PA, Vinks AA, Filipovich A,
Bleesing J, Jodele S, Jordan MB, et al. Alternate-day micafungin
antifungal prophylaxis in pediatric patients undergoing hematopoietic
stem cell transplantation: a pharmacokinetic study [published
correction appears in Biol Blood Marrow Transplant. 2011
Mar;17(3):441]. Biol Blood Marrow Transplant .
2010;16(10):1458-1462.
26. Neofytos D, Huang YT, Cheng K,
Cohen N, Perales MA, Barker J, et al. Safety and Efficacy of
Intermittent Intravenous Administration of High-Dose
Micafungin. Clin Infect Dis . 2015;61 Suppl 6(Suppl 6):S652-S661.
27. Manrique-Rodríguez S, Fernández-Llamazares CM. Standardization for
safety: a feasible challenge. Farm Hosp. 2020 May 1;44(3):79-80.
28. Cangemi G, Barco S, Bandettini R,
Castagnola E. Quantification of micafungin in human plasma by liquid
chromatography-tandem mass spectrometry [published correction appears
in Anal Bioanal Chem. 2014 May;406(13):3249]. Anal Bioanal
Chem . 2014;406(6):1795-1798.
29. Institute NC. Common toxicity criteria version 3.0. Available
at:http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcae_index.pdf
(last accessed 22 July 2015).
30. Kim R, Koh Y, Shin DY, Choe PG,
Kim NJ, Yoon SS, et al. The limited role of serum galactomannan assay in
screening for invasive pulmonary aspergillosis in allogeneic stem cell
transplantation recipients on micafungin prophylaxis: a retrospective
study. Blood Res . 2017;52(4):300-306.
31. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra
T, et al. Revised definitions of invasive fungal disease from the
European Organization for Research and Treatment of Cancer/Invasive
Fungal Infections Cooperative Group and the National Institute of
Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG)
Consensus Group. Clin Infect Dis . 2008;46(12):1813-1821.
32. Muilwijk EW, Maertens JA, van der
Velden W, Ter Heine R, Colbers A, Burger DM, et al. Pharmacokinetics of
extended dose intervals of micafungin in haematology patients:
optimizing antifungal prophylaxis. The Journal of antimicrobial
chemotherapy. 2018;73(11):3095-101.
33. Chandra S, Fukuda T, Mizuno K, Davies SM, Teusink-Cross A Torin R,
Marsh RA, Vinks A, Mehra P. Micafungin antifungal prophylaxis in
children undergoing HSCT: can we give higher doses, less frequently? A
pharmacokinetic study. J AntimicrobChemother 2018.
34. Funaki T, Miyairi I. Breakthrough
Candidemia In Children On Micafungin. The Pediatric infectious disease
journal. 2018;37(12):1258-60.
35. Chan TS, Gill H, Hwang YY, Sim J,
Tse AC, Loong F, et al. Breakthrough invasive fungal diseases during
echinocandin treatment in high-risk hospitalized hematologic patients.
Annals of hematology. 2014;93(3):493-8.
36. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin
DS, Alexander BD.Breakthrough invasive candidiasis in patients on
micafungin,J Clin Microbiol,2010;48(7):2373-80.
37. Jean El Cheikh EC, Patrice C, Jean-Hugues D, ophieDucastelle-Leprêt
D-L, Elsa D, Raoul H. Micafungin prophylaxis in routine medical practice
in adult and pediatric patients with hematological malignancy: a
prospective, observational study in France. Diagn Microbiol Infect Dis.
2019 Jul;94(3):268–73.
38. EUCAST. The European Committee on
Antimicrobial Susceptibility Testing. Breakpoint tables for
interpretation of MICs and zone diameters, version 8.0. 2018. Available
from: http://www.eucast.org/clinical_breakpoints/.
39. Clinical and Laboratory Standards
Institute . Reference method for broth dilution antifungal
susceptibility testing of yeasts; 4thInformational Supplement. CLSI
document M27-S4. Wayne: Clinical and Laboratory Standards Institute;
2012.
40. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of
clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and
micafungin: a head-to-head comparison using the CLSI M38-A2 broth
microdilution method. J Clin Microbiol 2009; 47: 3323–5
41. Edwards AY, Skolnik JM, Dombrowsky E et al. Modeling and simulation
approaches to evaluate pharmacokinetic sampling contamination from
central venous catheters in pediatric pharmacokinetic studies of
actinomycin-D:a report from the children’s oncology group. Cancer
Chemother Pharmacol 2012; 70: 83–94.